Evaxion extends its AI-Immunology platform into autoimmune diseases. Platform expansion into new disease area may support future growth without immediate major financial shifts.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 5.58 | 5.95 | 23.23 | 14.00 |
| Receivables | 0.82 | 1.54 | 0.87 | 0.84 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 8.35 | 8.77 | 24.90 | 15.86 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.69 | 2.97 | 2.19 | 1.59 |
| ST’ Debt | 0.16 | 0.16 | 0.19 | 0.19 |
| Other | 2.90 | — | 0.29 | 0.15 |
| 7.08 | 4.37 | 4.26 | 3.13 |
| 10y | 5y | 3y | |
| Sales | — | — | — |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | 0.04 | 7.49 | — |
7.53
|
| ’24 | 0.05 | 0.15 | 3.02 | — |
3.34
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (8.26) | — | — |
—
|
| ’25 | — | (7.72) | — | — |
(6.62)
|
| ’24 | — | (8.98) | — | — |
(12.94)
|
| ’23 | — | (11.29) | — | — |
(17.69)
|
| ’22 | (8.19) | (5.19) | — | — |
(25.77)
|
| ’21 | (4.03) | (7.49) | (6.29) | (4.11) |
(21.93)
|
| ’20 | (2.95) | (2.30) | (2.76) | (4.42) |
(12.44)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | (8.26) | — | — |
—
|
| ’25 | — | (7.72) | — | — |
(6.64)
|
| ’24 | — | (8.98) | — | — |
(12.94)
|
| ’23 | — | (11.32) | — | — |
(17.78)
|
| ’22 | (8.37) | (5.27) | — | — |
(26.07)
|
| ’21 | (4.38) | (8.00) | (6.63) | (4.29) |
(23.29)
|
| ’20 | (3.01) | (2.35) | (2.77) | (4.49) |
(12.62)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.44) | (0.50) | — | — |
—
|
| ’25 | (0.29) | (0.76) | 0.73 | — |
(1.00)
|
| ’24 | 0.03 | (0.60) | (0.20) | — |
(0.20)
|
| ’23 | (0.24) | (10.50) | (2.10) | — |
(4.05)
|
| ’22 | (12.50) | (10.00) | (0.24) | (0.29) |
(49.00)
|
| ’21 | (11.50) | (18.00) | (13.50) | (19.50) |
(63.00)
|
| ’20 | — | (0.19) | — | (0.26) |
(48.50)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | ‡‡‡‡‡ | 75.50 | 23.50 | 4.15 | 1.20 | — | — | — |
Low Price
|
| — | — | — | — | — | ‡‡‡‡‡ | 233.65 | 107.00 | 68.05 | 12.15 | — | — | — |
High Price
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 60 | 49 | 46 | 46 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.07 | 0.16 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | — | — | 0.07 | 3.34 | 7.53 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 100.00% | 100.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (23.94) | (22.91) | (11.35) | (8.61) | ‡‡‡‡‡ | — | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | (31,390.41%) | (339.56%) | (114.44%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (23.17) | (22.12) | (10.57) | (7.71) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.57 | 0.62 | 0.61 | 0.62 | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.13 | 3.12 | 1.17 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (49.00) | (4.05) | (0.20) | (1.00) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (54.51) | (32.36) | (12.06) | (1.03) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.62) | (0.16) | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (55.13) | (32.52) | (12.06) | (1.04) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.56 | (8.65) | (1.54) | 2.66 | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.47 | 0.55 | 1.07 | 6.41 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| — | — | — | — | — | — | — | 0.00 | 0.00 | 2.84 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | — | — | — | — | — | 0.00 | 0.00 | 1.78 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | — | — | — | — | — | 0.00 | 0.00 | 1.33 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| — | — | — | — | — | — | — | (3.61) | (0.25) | (0.42) | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (25.77) | (17.69) | (12.94) | (6.62) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.29) | (0.09) | — | (0.01) | — | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (26.07) | (17.78) | (12.94) | (6.64) | — | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.22 | 1.27 | 4.40 | 20.64 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.95 | 10.54 | 9.79 | 7.14 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.23) | 4.96 | 3.84 | (16.09) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.30 | (4.73) | (1.65) | 17.04 | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (74.51%) | (126.74%) | (83.29%) | (37.69%) | ‡‡‡‡‡ | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (311.38%) | (5,979.80%) | (421.78%) | (608.14%) | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (113.74%) | (1,238.11%) | 331.20% | (100.18%) | ‡‡‡‡‡ | — | — |
ROE
|
Evaxion A/S (EVAX), a trailblazing Danish biotech harnessing AI for precision immunotherapy against cancer and infectious diseases, is poised for a dramatic rebound from its recent lows. Analyst consensus points to a staggering 230% upside, with high-end targets nearing 380%, fueled by explosive revenue growth—from a mere $73,000 in 2023 to $3.34 million in 2024—and narrowing losses amid strategic partnerships with giants like Sanofi and Janssen. As biotech shakes off post-pandemic woes and high-rate pressures, EVAX’s pivot to commercialization signals an inflection point, with improving margins and lean operations amplifying its disruptive potential.
Forecasts paint an exhilarating profitability arc: revenue set to surge 125% to $7.5 million in 2025, then leap to $33.9 million by 2027 (454% from 2026), flipping EBT positive at $42 million in 2026 and delivering positive EPS of $0.06 by 2027. Despite past dilution and balance sheet strains, net debt is shrinking, working capital is up 248%, and EV/Sales multiples scream undervaluation at 3.71x forward versus peers’ 5-10x. Free cash flow trends improve, underscoring operational efficiency in this high-margin AI-driven space.
With macro tailwinds like cooling inflation, prospective rate cuts, and surging immunotherapy demand, EVAX offers explosive upside for risk-tolerant investors eyeing biotech’s revival. Key 2026 milestones could catalyze a re-rating, but execution risks loom—dive into the full analysis for the charts, catalysts, and valuation details that make this micro-cap innovator a high-conviction bet.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.